{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"}],"units":"Participants"}],"description":"Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as at least a 20% increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) and the sum must also demonstrate an absolute increase of at least 5mm, or unequivocal progression of existing non-target lesions, or the appearance of new lesions. Estimated at 3 months using the Kaplan-Meier method.","groups":[{"description":"Patients receive afatinib dimaleate PO QD on days 1-42. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.\n\nafatinib dimaleate: Given PO\n\nlaboratory biomarker analysis: Correlative studies","id":"OG000","title":"Treatment (Afatinib)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Analysis population included those in the main Phase II study","reportingStatus":"POSTED","timeFrame":"3 months","title":"Progression-free Survival (PFS)","type":"PRIMARY","unitOfMeasure":"Participants"}